Myriad Genetics Inc. has announced the presentation of 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. The studies will feature products including the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research will be presented through a series of poster sessions, with topics covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors. The results will be presented during the conference on November 7 and 8, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570231-en) on November 06, 2025, and is solely responsible for the information contained therein.